Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lenny Dang

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Chemistry & Biology|September 25, 2012
Small molecule activation of PKM2 in cancer cells induces serine auxotrophyCharles Kung, Jeff Hixon, Sung Choe, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Molecular Cancer Therapeutics|October 21, 2020
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate DehydrogenaseGabrielle McDonald, Victor Chubukov, John Coco, et al.
Journal of Inherited Metabolic Disease|July 30, 2016
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse modelFang Wang, Jeremy Travins, Zhizhong Lin, et al.
ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersJaneta Popovici-Muller, René M Lemieux, Erin Artin, et al.
Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.
Nature Chemical Biology|August 28, 2012
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesisDimitrios Anastasiou, Yimin Yu, William J Israelsen, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Chemistry & Biology|September 25, 2012
Small molecule activation of PKM2 in cancer cells induces serine auxotrophyCharles Kung, Jeff Hixon, Sung Choe, et al.
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Molecular Cancer Therapeutics|October 21, 2020
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate DehydrogenaseGabrielle McDonald, Victor Chubukov, John Coco, et al.
Journal of Inherited Metabolic Disease|July 30, 2016
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse modelFang Wang, Jeremy Travins, Zhizhong Lin, et al.
ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersJaneta Popovici-Muller, René M Lemieux, Erin Artin, et al.
Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.
Nature Chemical Biology|August 28, 2012
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesisDimitrios Anastasiou, Yimin Yu, William J Israelsen, et al.
Pageof 4